Plasma of human adults contains an oxytocin, vasotocin-like (OT-VT) immunoreactive material that is estrogen responsive in both males and females and the levels of which are elevated during pregnancy. Although OT-VT is immunoreactive with an antiserum raised against synthetic arginine vasotocin (AVT), the elution profile of OT-VT by high-performance liquid chromatography (HPLC) is distinct from AVT, arginine vasopressin (AVP) or oxytocin (OT). Because the fetus is also exposed to high estrogen levels during pregnancy and AVT has been reported to be present in human fetal pituitaries, cord blood samples from 16 vaginally delivered human newborn infants were examined for evidence of OT-VT and AVT. Analysis of an extracted pool of cord blood plasma by HPLC revealed 4 peaks (I-IV) of AVT-like immunoreactivity. Peaks II and IV coeluted with synthetic AVP and OT, respectively, and were attributable to cross-reaction of the AVT antiserum with these peptides. Peak I was identified as AVT on the basis of its coelution with synthetic AVT. Peak III eluted in a manner identical with OT-VT. These results indicate that human newborn plasma contains at least three neurohypophysial peptides, AVP, OT and AVT. Additionally, newborn plasma contains an AVT-like immunoreactive material that is distinct from AVT, AVP and OT, but is identical with a novel OT-VT material observed in plasma of estrogen-primed adults. The physiological significance of AVT and OT-VT in newborn plasma remains to be determined.

Keywords:
Arginine vasotocin, Oxytocin, Arginine vasopressin
This content is only available via PDF.
© 1988 S. Karger AG, Basel
1988
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.